Authors

Latest:

Not All Stage I and II Endometrial Cancers Are Alike

A recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.

Helen J. Ross, MD

Latest:

Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLC

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

Francisco Hernandez-Ilizaliturri, MD

Francisco J. Hernandez-Ilizaliturri, MD is a professor of oncology in the Department of Medicine – Lymphoma, director of the Lymphoma Research, head of the Lymphoma Translational Research Lab, associate professor in the Department of Immunology, at Roswell Park Comprehensive Cancer Center; and clinical professor in the Department of Medicine at the Jacobs School of Medicine and Biomedical Sciences, University at Buffalo in New York.

Latest:

Dr Hernandez-Ilizaliturri on the Design of an Observational Study of Immunologic Changes With Venetoclax in CLL

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

Manmeet Singh Ahluwalia, MD

Latest:

Dr Ahluwalia on the SURVIVE Trial of SurVaxM Plus Chemoradiation in Newly-Diagnosed Glioblastoma

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses the phase 2b SURVIVE trial of SurVaxM plus chemoradiation in newly-diagnosed glioblastoma.

Saad Z. Usmani, MD, Atrium Health

Latest:

Dr. Usmani on the Rapidly Evolving Landscape in Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.

Tae Min Kim, MD, PhD

Latest:

Dr Kim on The Efficacy and Safety of Odronextamab in R/R MZL

Tae Min Kim, MD, PhD, discusses the efficacy of odronextamab monotherapy in patients with relapsed/refractory marginal zone lymphoma.

Hans Lee, MD

Hans Lee, MD, is the director of Myeloma Research at the Sarah Cannon Research Institute

Latest:

FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Kerry R. Schaffer, MD

Latest:

New Framework for Genetic Testing in Prostate Cancer Takes Shape

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

University of Iowa Holden Comprehensive Cancer Center

Latest:

New Breast Center at UI Health Care Aims to Ease the Cancer Journey for Patients

The new breast center at UI Holden Comprehensive Cancer Center aims to make the cancer journey easier and less stressful for patients by providing access to the state's most advanced cancer services in 1 convenient location.

Erin Cobain, MD

Latest:

Dr Cobain on the Importance of Molecular Testing in Metastatic Breast Cancer

Erin Frances Cobain, MD, discusses the importance of molecular testing in patients with metastatic breast cancer.

Julia Foldi, MD, PhD

Latest:

Beyond Hyperglycemia: Complete Safety Management for PI3K Inhibitor Combinations

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Ruemu E. Birhiray, MD

Ruemu E. Birhiray, MD, is a medical oncologist and hematologist at Hematology Oncology of Indiana. He is also a member of the American Society of Clinical Oncology, American Society of Hematology, American Medical Association, and Wisconsin Medical Society.

Ramez Kouzy, MD

Latest:

Dr Kouzy on the Creation of a Centralized Resource to Inform AI Use in Radiation Oncology

Ramez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.

Benjamin Solomon, MBBS, PhD, FRACP

Latest:

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC

Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Haris Ali, MD, City of Hope

Latest:

Multidisciplinary Approaches to GVHD

Medical experts discuss multidisciplinary approaches to GVHD.

Razane El Hajj Chehade, MD

Latest:

Dr Hajj Chehade on Potential Risk Factors for irAE Development in mRCC

Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.

Jill Gilbert, MD

Jill Gilbert, MD, is a Professor of Medicine and the Vice Chair of Professional Development for the Department of Medicine Vanderbilt University Medical Center

Latest:

Being Coachable Is Vital to Success

Jill Gilbert, MD discusses how being coachable and using feedback effectively can drive personal growth, team success, and continuous professional improvement.

Marina Baretti, MD

Latest:

Dr Baretti on Entinostat Plus Nivolumab in Advanced PDAC

Marina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma.

Icro Meattini, MD

Icro Meattini, MD, an associate professor in the Department of Clinical and Experimental Biomedical Sciences at the University of Florence; as well as a clinical oncologist in the Radiation Oncology Unit in the Oncology Department and head of the Breast Unit and Breast Cancer Multidisciplinary Team at Florence University Hospital

Latest:

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

Icro Meattini, MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

Thorvardur Halfdanarson, MD

Latest:

Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRC

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.